Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.

Biotechnology

Angiocrine Bioscience

Paul Finnegan

Kathy K. Park

Gayle Bresnahan

Geoff Davis

Margie Breneman

John R. Jaskowiak

Lee Landeen

John Lomoro

John K. Fraser

Daniel J. Nolan

Michael Ginsberg

Executive Administration

Leadership Team

Advisory Team

Research and Development

Clinical Development Team

Teams at Angiocrine Bioscience

Executive Administration

Leadership Team

Advisory Team

Research and Development

Clinical Development Team